Open-label study to assess the safety and immunogenicity of etanercept SFP when administered to subjects diagnosed with rheumatoid arthritis.

Trial Profile

Open-label study to assess the safety and immunogenicity of etanercept SFP when administered to subjects diagnosed with rheumatoid arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2009

At a glance

  • Drugs Etanercept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Sponsors Amgen
  • Most Recent Events

    • 23 Mar 2008 Patient exclusions added from ClinicalTrials.gov update.
    • 27 Dec 2007 Status changed from in progress to completed as reported by ClinicalTrials.gov.
    • 09 Aug 2007 Status changed from initiated to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top